Quanterix announces Anthem Blue Cross Blue Shield coverage for LucentAD Complete Alzheimer's blood test

Elevance Health
Quanterix Corporation

Elevance Health

ELV

0.00

Quanterix Corporation

QTRX

0.00
  • Quanterix posted a press release noting Anthem Blue Cross and Blue Shield commercial coverage for LucentAD Complete blood-based Alzheimer’s testing from July 1, 2026.
  • Coverage applies when medical-necessity criteria are met under LAB.00046: Testing for Biochemical Markers for Alzheimer Disease.
  • Release also cited a peer-reviewed study reporting diagnostic parity versus an IP-MS method; multi-analyte algorithm cut indeterminate results about three-fold.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260714466817) on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.